Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center studyArticle Published on 2021-01-012023-07-06 Journal: Journal of infection and chemotherapy : official j [Category] SARS, [키워드] body mass index COVID-19 Illness severity Methylprednisolone systemic inflammation Tocilizumab [DOI] 10.1016/j.jiac.2020.09.022 PMC 바로가기
A systematic review on treatment-related mucocutaneous reactions in COVID-19 patientsCOVID-19 환자의 치료 관련 점막 피부 반응에 대한 체계적인 검토Article Published on 2021-01-012022-09-11 Journal: Dermatologic therapy [Category] SARS, 치료제, [키워드] Adverse drug reaction Adverse drug reactions adverse effect adverse effects Adverse reaction AGEP Anti-viral antibiotic Antibiotics antimalarial antimalarial drug Antimalarial drugs Antiviral article articles Azithromycin Better biologic clinical trials cohorts Combination Corona virus coronavirus COVID-19 COVID-19 patient covid-19 therapies COVID-19 treatments Cutaneous cutaneous drug reactions database databases Dermatology drug drug eruption drug eruptions drug induced drug reaction drug usage enoxaparin eruption Favipiravir Frequency HCQ highest human coronavirus Hydroxychloroquine induce initial Jak JAK inhibitor Janus kinase Janus kinase inhibitor Kinase inhibitor less Lopinavir Lopinavir/ritonavir maculopapular rashe maculopapular rashes management MOST mucocutaneous mucosal novel human coronavirus (SARS-CoV-2) occur pandemic potentially life-threatening prevalent rashes reaction Reactions Ritonavir Side effect Side effects skin skin reactions steroid Steroids syndrome systematic review targeted therapy TNF-α TNF-α inhibitor Tocilizumab Treatment treatment-induced treatment-reaction treatment-related. Type Usage Vasculitis [DOI] 10.1111/dth.14662 PMC 바로가기 [Article Type] Article
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?COVID-19 발생 시 류마티스 질환에 대한 생물학적 제제: 친구 또는 적?Observational Study Published on 2021-01-012022-09-12 Journal: RMD Open [Category] 임상, 진단, [키워드] affected age analysed Autoimmunity Baricitinib Biological agent biological therapy cardiovascular disease Care Community Comorbidities covariate COVID-19 COVID-19 infection cytokine production determine diagnosed diagnosed with COVID-19 Diagnosis disease dose drug Epidemiology exacerbated form General population glucocorticoid group hospital Hospital admission hospitalisation hypertension IL-1 IL-6 IL-6 inhibitor IL-6 inhibitors immunosuppressed patient incidence of COVID-19 incidence rate Inflammation Inflammatory inhibitor inhibitors intensive care IQR JAK inhibitor less lowest management manifestation median age multivariate logistic regression no difference no significant difference occur Older outbreak outpatient clinic Patient patients patients died patients treated patients with COVID-19 performed positive prognosis of patient proportions Protective protective effect protective factor raised receiving required retrospective rheumatic disease Rheumatic diseases rheumatological rheumatology risk risk factor sarilumab SARS-CoV-2 severe COVID-19 disease Sex smoker Spain suggested tested therapy Tocilizumab Treatment with COVID-19 [DOI] 10.1136/rmdopen-2020-001439 PMC 바로가기 [Article Type] Observational Study
Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy면역억제 요법을 받는 중증 COVID-19 환자에서 B형 간염 재활성화 위험 낮음Article Published on 2021-01-012022-09-11 Journal: Journal of viral hepatitis [Category] B형 간염, SARS, 진단, 치료기술, 치료제, [키워드] analysed Antiviral both group both groups Corticosteroids Course COVID-19 detectable develop entecavir excessive immune response feature Follow-up HBsAg HBV HBV infection Hepatitis hepatitis B Hepatitis B virus hospital hospital discharge IL-6 IL-6 receptor antagonist IL-6 receptor antagonists immune immunosuppressive immunosuppressive therapies immunosuppressive therapy Immunosuppressive treatment Immunotherapy include infected with SARS-CoV-2 Infection male median age Patient patients positive Prophylaxis proportion prospective cohort study Reactivation receive receptor antagonists resolved respiratory respiratory symptoms risk Safe serum severe COVID-19 severe respiratory symptom severe respiratory symptoms therapy Tocilizumab treated [DOI] 10.1111/jvh.13410 PMC 바로가기 [Article Type] Article
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ replyCOVID-19에서 토실리주맙 사용에 대한 근거 및 증거: 체계적인 검토. 저자의 답변Comment Published on 2021-01-012022-09-12 Journal: Pulmonology [Category] MERS, SARS, 진단, [키워드] Evidence rationale systematic review Tocilizumab [DOI] 10.1016/j.pulmoe.2020.10.003 PMC 바로가기 [Article Type] Comment
Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the managementSARS-CoV-2 감염의 성인 호흡부전 예방을 위한 토실리주맙의 조기 사용 및 관리에서 인터루킨-6 수준의 활용Article Published on 2021-01-012022-09-12 Journal: Journal of medical virology [Category] SARS, 진단, [키워드] acute respiratory syndrome Administered Analysis appear C-reactive protein changes Computed tomography coronavirus CRP Cytokine release syndrome D-dimer D-dimer level D-dimer levels decrease dropped early treatment evaluated expired females ferritin IL-6 IL-6 level IL-6 levels Infection interleukin-6 investigated lactate dehydrogenase LDH males management mechanical ventilation Methylprednisolone nine outcomes Oxygen requirement Patient patients with SARS-CoV-2 performed Pneumonia Severity Index procalcitonin prognostic reduce reduced required respiratory Respiratory failure SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-positive patient TCZ the cytokine storm the median therapy Tocilizumab [DOI] 10.1002/jmv.26288 PMC 바로가기 [Article Type] Article
COVID-19 Post-Infectious Encephalitis Presenting With Delirium as an Initial Manifestation섬망을 초기 징후로 나타내는 COVID-19 감염 후 뇌염Case Reports Published on 2021-01-012022-09-11 Journal: Journal of investigative medicine high impact case [Category] 치료기술, [키워드] abnormal behavior Abnormalities acute respiratory syndrome autoantibody cerebrospinal fluid coronavirus coronavirus disease COVID-19 COVID-19 pneumonia delirium Dexamethasone discharge elevated Encephalitis Fever Immunoglobulin immunoglobulin therapy immunosuppressive immunosuppressive therapy infectious encephalitis inflammatory change initial initial symptom Intravenous immunoglobulin intravenous methylprednisolone magnetic resonance imaging manifestation Methylprednisolone neuronal Older Older adults Patient pleocytosis post-infectious encephalitis. protein concentration respiratory respiratory symptoms RNA SARS-CoV-2 Severe acute respiratory syndrome Severe COVID-19 pneumonia surface protein the patient therapy Tocilizumab with COVID-19 [DOI] 10.1177/23247096211029787 PMC 바로가기 [Article Type] Case Reports
Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report중증 코비드-19 치료에 토실리주맙과 중간엽 기질 세포의 병용: 증례 보고Case Reports Published on 2021-01-012022-09-12 Journal: Cell transplantation [Category] 진단, [키워드] acute respiratory syndrome adverse effects Case report Combination Combined coronavirus COVID-19 critical condition decrease Dexamethasone drug event Hospital stay Mesenchymal stromal cells Mortality nasal catheter pandemic Patient prophylactic dose public health report reported respond Safe SARS-CoV-2 specific treatment standard procedure stromal cell Symptoms tested the disease therapy Tocilizumab treated Treatment UC-MSC umbilical Umbilical cord [DOI] 10.1177/09636897211021008 PMC 바로가기 [Article Type] Case Reports
Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy화학면역요법으로 치료받은 비소세포폐암 환자의 코로나19 폐렴에 대한 토실리주맙Case Reports Published on 2021-01-012022-09-12 Journal: Clinical lung cancer [Category] 진단, [키워드] Abstract Chemoimmunotherapy COVID-19 lung Non–small-cell lung cancer Tocilizumab [DOI] 10.1016/j.cllc.2020.08.002 PMC 바로가기 [Article Type] Case Reports
Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusionSARS-CoV-2 감염 환자의 토실리주맙 투여: 피하 주사 대 정맥 주입Comment Published on 2021-01-012022-09-12 Journal: Journal of medical virology [Category] SARS, 진단, [키워드] Abstract administration COVID-19 Cytokine storm syndrome injection intravenous patients with SARS-CoV-2 pharmacokinetic Subcutaneous Tocilizumab [DOI] 10.1002/jmv.26124 PMC 바로가기 [Article Type] Comment